Dosimetry of 239Pu in dogs that inhaled monodisperse aerosols of 239PuO2.
Existing data from human exposure cases and experimental animal studies on the fate and dosimetry of inhaled insoluble Pu particles are inadequate to provide a comprehensive description and evaluation of the tissues at risk from the alpha radiations of Pu. To improve our knowledge of the dosimetry of inhaled insoluble 239PuO2, this paper describes the uptake and retention of 239Pu in the tissues of dogs that received single inhalation exposures to monodisperse aerosols of 239PuO2. These data include times through 3 years after exposure. Using analytical functions fitted to each tissue data set, 1100-day radiation doses were calculated for lung, liver, skeleton, kidney, spleen, and tracheobronchial, mediastinal, sternal, hepatic, mandibular, and retropharyngeal lymph nodes. The dosimetry results suggest that the lung and lymph nodes associated with lymphatic drainage of the respiratory tract are the principal sites of alpha irradiation. However, the doses for the different respiratory tract lymph nodes vary by a factor of 2000, suggesting that assuming equivalent doses to respiratory tract lymph nodes is not appropriate. Other tissues receive radiation doses also but at levels one to three orders of magnitude less than the lung. Particle size dependence on uptake and retention was noted for the skeleton, mediastinal lymph nodes, hepatic lymph nodes, retropharyngeal lymph nodes, and mandibular lymph nodes.
D000280:Administration, Inhalation; D000336:Aerosols; D000396:Air Pollutants, Radioactive; D000512:Alpha Particles; D000818:Animals; D004285:Dogs; D004307:Dose-Response Relationship, Radiation; D006207:Half-Life; D008168:Lung / Q000032:analysis; D008198:Lymph Nodes / Q000032:analysis; D010316:Particle Size; D011005:Plutonium / Q000008:administration & dosage / Q000032:analysis*; D011874:Radiometry; D014018:Tissue Distribution
D000336:Aerosols; D000396:Air Pollutants, Radioactive; D011005:Plutonium